Thomas Armor

893 total citations
16 papers, 685 citations indexed

About

Thomas Armor is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Thomas Armor has authored 16 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Thomas Armor's work include Radiopharmaceutical Chemistry and Applications (13 papers), Prostate Cancer Treatment and Research (12 papers) and Medical Imaging Techniques and Applications (3 papers). Thomas Armor is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (13 papers), Prostate Cancer Treatment and Research (12 papers) and Medical Imaging Techniques and Applications (3 papers). Thomas Armor collaborates with scholars based in United States, Hungary and Belgium. Thomas Armor's co-authors include John W. Babich, Kevin Maresca, John L. Joyal, Stanley J. Goldsmith, Shankar Vallabhajosula, James B. Stubbs, Lilja B. Sólnes, Nancy Stambler, Michael G. Stabin and Neil A. Petry and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Nuclear Medicine and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Thomas Armor

15 papers receiving 683 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Armor United States	8	460	409	189	128	106	16	685
Jessica Jensen United States	5	336 0.7×	471 1.2×	119 0.6×	163 1.3×	186 1.8×	10	735
Shozo Okamoto Japan	17	768 1.7×	626 1.5×	149 0.8×	79 0.6×	273 2.6×	36	1.1k
Vincent A. DiPippo United States	12	210 0.5×	199 0.5×	131 0.7×	133 1.0×	137 1.3×	29	552
Sarah Chittenden United Kingdom	16	591 1.3×	312 0.8×	150 0.8×	92 0.7×	57 0.5×	34	784
Andrew Prideaux United States	9	456 1.0×	248 0.6×	78 0.4×	32 0.3×	23 0.2×	11	571
Seval Beykan Germany	9	627 1.4×	507 1.2×	327 1.7×	21 0.2×	43 0.4×	13	843
Mark Scalzo Australia	7	1.1k 2.4×	1.1k 2.6×	398 2.1×	35 0.3×	117 1.1×	10	1.3k
José Flávio Gomes Marin Brazil	10	265 0.6×	357 0.9×	168 0.9×	64 0.5×	39 0.4×	28	568
PL Jager Netherlands	7	323 0.7×	141 0.3×	58 0.3×	56 0.4×	82 0.8×	23	631
Marcus Bronzel Germany	6	828 1.8×	683 1.7×	288 1.5×	21 0.2×	45 0.4×	12	940

Countries citing papers authored by Thomas Armor

Since Specialization

Citations

This map shows the geographic impact of Thomas Armor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Armor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Armor more than expected).

Fields of papers citing papers by Thomas Armor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Armor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Armor. The network helps show where Thomas Armor may publish in the future.

Co-authorship network of co-authors of Thomas Armor

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Armor. A scholar is included among the top collaborators of Thomas Armor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Armor. Thomas Armor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Juneau, Daniel, Fred Saad, Alejandro Berlín, et al.. (2021). Preliminary Dosimetry Results from a First-in-Human Phase I Study Evaluating the Efficacy and Safety of [225Ac]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors. 62. 74–74. 5 indexed citations

Juergens, Rosalyn A., Katherine Zukotynski, Daniel Juneau, et al.. (2019). A phase I study of [²²⁵Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS3152–TPS3152. 17 indexed citations

Pryma, Daniel A., Bennett B. Chin, Richard B. Noto, et al.. (2018). Efficacy and Safety of High-Specific-Activity ¹³¹I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. Journal of Nuclear Medicine. 60(5). 623–630. 191 indexed citations

Rathke, Hendrik, Ali Afshar‐Oromieh, Frederik L. Giesel, et al.. (2018). Intraindividual Comparison of ^99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine. 59(9). 1373–1379. 30 indexed citations

Afshar‐Oromieh, Ali, Uwe Haberkorn, Christian M. Zechmann, et al.. (2017). Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging. 44(6). 950–959. 67 indexed citations

Goffin, Karolien, Steven Joniau, Péter Tenke, et al.. (2017). Phase 2 Study of ^99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. Journal of Nuclear Medicine. 58(9). 1408–1413. 54 indexed citations

Tenke, Péter, Steven Joniau, Karolien Goffin, et al.. (2014). Correlation of Technetium Tc99m trofolastat chloride (MIP-1404) uptake using SPECT/CT with histopathology: A phase 2 study of prostate cancer (PCa) patients undergoing radical prostatectomy (RP) with extended lymph node dissection (ePLND). European Journal of Nuclear Medicine and Molecular Imaging. 41. 2 indexed citations

Chin, Bennett B., James F. Kronauge, F.J. Femia, et al.. (2014). Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free ¹²³I-Iobenguane. Journal of Nuclear Medicine. 55(5). 765–771. 18 indexed citations

Tenke, Péter, Steven Joniau, Kevin M. Slawin, et al.. (2014). 728 A phase 2 study of 99m TC-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) compared to histopathology: An interim analysis. European Urology Supplements. 13(1). e728–e728a. 1 indexed citations

10.

Vallabhajosula, Shankar, Anastasia Nikolopoulou, John W. Babich, et al.. (2014). ^99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine. 55(11). 1791–1798. 116 indexed citations

11.

Slawin, Kevin M., Péter Tenke, Steven Joniau, et al.. (2014). A phase 2 study of ^99mTc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.. Journal of Clinical Oncology. 32(15_suppl). e16003–e16003. 1 indexed citations

12.

Slawin, Kevin M., William J. Ellis, Péter Tenke, et al.. (2014). A phase II study of ^99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.. Journal of Clinical Oncology. 32(4_suppl). 94–94. 3 indexed citations

13.

Vallabhajosula, Shankar, Joseph R. Osborne, Anastasia Nikolopoulou, et al.. (2013). PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): Phase I studies with 99mTc-MIP-1404. 54(5710). 281–281. 3 indexed citations

14.

Barrett, John, Robert E. Coleman, Stanley J. Goldsmith, et al.. (2013). First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. Journal of Nuclear Medicine. 54(3). 380–387. 171 indexed citations

15.

Osborne, Joseph R., Naveed Akhtar, Shankar Vallabhajosula, et al.. (2012). Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology. 30(5_suppl). 173–173. 6 indexed citations

16.

Coleman, Robert E., John Barrett, Arif Hussain, et al.. (2011). Prostate-specific membrane antigen (PSMA)–targeted imaging of metastatic prostate cancer (PCa) via small molecule inhibitors: Comparison to bone scan, CT/MRI, and¹¹¹In capromab.. Journal of Clinical Oncology. 29(15_suppl). 4658–4658.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact